James W T Toh1,2,3,4, Kevin Phan5, Faizur Reza5, Pierre Chapuis6, Kevin J Spring7. 1. Department of Surgery, Division of Colorectal Surgery, Westmead Hospital, Sydney, NSW, Australia. james.toh@sydney.edu.au. 2. Discipline of Surgery, Sydney Medical School, University of Sydney, Sydney, NSW, Australia. james.toh@sydney.edu.au. 3. Discipline of Surgery, The University of New South Wales, Sydney, NSW, Australia. james.toh@sydney.edu.au. 4. Medical Oncology, Ingham Institute for Applied Medical Research, School of Medicine Western Sydney University and South Western Clinical School, University of New South Wales, NSW, Sydney, Australia. james.toh@sydney.edu.au. 5. Department of Surgery, Division of Colorectal Surgery, Westmead Hospital, Sydney, NSW, Australia. 6. Discipline of Surgery, Sydney Medical School, University of Sydney, Sydney, NSW, Australia. 7. Medical Oncology, Ingham Institute for Applied Medical Research, School of Medicine Western Sydney University and South Western Clinical School, University of New South Wales, NSW, Sydney, Australia.
Abstract
INTRODUCTION: For the past two decades, microsatellite instability (MSI) has been reported as a robust clinical biomarker associated with survival advantage attributed to its immunogenicity. However, MSI is also associated with high-risk adverse pathological features (poorly differentiated, mucinous, signet cell, higher grade) and exhibits a double-edged sword phenomenon. We performed a systematic review and meta-analysis to evaluate the rate of dissemination and the prognosis of early and advanced stage colorectal cancer based on MSI status. METHODS: A systematic literature search of original studies was performed on Ovid searching MEDLINE, Embase, Cochrane Database of Systematic Reviews, American College of Physicians ACP Journal Club, Database of Abstracts of Reviews of Effects DARE, Clinical Trials databases from inception of database to June 2019. Colorectal cancer, microsatellite instability, genomic instability and DNA mismatch repair were used as key words or MeSH terms. The Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) reporting guideline was followed. Data were pooled using a random-effects model with odds ratio (OR) as the effect size. Statistical analysis was performed using RevMan ver 5.3 Cochrane Collaboration. RESULTS: From 5288 studies, 136 met the inclusion criteria (n = 92,035; MSI-H 11,746 (13%)). Overall, MSI-H was associated with improved OS (OR, 0.81; 95% CI 0.73-0.90), DFS (OR, 0.73; 95% CI 0.66-0.81) and DSS (OR, 0.69; 95% CI 0.52-0.90). Importantly, MSI-H had a protective effect against dissemination with a significantly lower rate of lymph node and distant metastases. By stage, the protective effect of MSI-H in terms of OS and DFS was observed clearly in stage II and stage III. Survival in stage I CRC was excellent irrespective of MSI status. In stage IV CRC, without immunotherapy, MSI-H was not associated with any survival benefit. CONCLUSIONS: MSI-H CRC was associated with an overall survival benefit with a lower rate of dissemination. Survival benefit was clearly evident in both stage II and III CRC, but MSI-H was neither a robust prognostic marker in stage I nor stage IV CRC without immunotherapy.
INTRODUCTION: For the past two decades, microsatellite instability (MSI) has been reported as a robust clinical biomarker associated with survival advantage attributed to its immunogenicity. However, MSI is also associated with high-risk adverse pathological features (poorly differentiated, mucinous, signet cell, higher grade) and exhibits a double-edged sword phenomenon. We performed a systematic review and meta-analysis to evaluate the rate of dissemination and the prognosis of early and advanced stage colorectal cancer based on MSI status. METHODS: A systematic literature search of original studies was performed on Ovid searching MEDLINE, Embase, Cochrane Database of Systematic Reviews, American College of Physicians ACP Journal Club, Database of Abstracts of Reviews of Effects DARE, Clinical Trials databases from inception of database to June 2019. Colorectal cancer, microsatellite instability, genomic instability and DNA mismatch repair were used as key words or MeSH terms. The Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) reporting guideline was followed. Data were pooled using a random-effects model with odds ratio (OR) as the effect size. Statistical analysis was performed using RevMan ver 5.3 Cochrane Collaboration. RESULTS: From 5288 studies, 136 met the inclusion criteria (n = 92,035; MSI-H 11,746 (13%)). Overall, MSI-H was associated with improved OS (OR, 0.81; 95% CI 0.73-0.90), DFS (OR, 0.73; 95% CI 0.66-0.81) and DSS (OR, 0.69; 95% CI 0.52-0.90). Importantly, MSI-H had a protective effect against dissemination with a significantly lower rate of lymph node and distant metastases. By stage, the protective effect of MSI-H in terms of OS and DFS was observed clearly in stage II and stage III. Survival in stage I CRC was excellent irrespective of MSI status. In stage IV CRC, without immunotherapy, MSI-H was not associated with any survival benefit. CONCLUSIONS:MSI-H CRC was associated with an overall survival benefit with a lower rate of dissemination. Survival benefit was clearly evident in both stage II and III CRC, but MSI-H was neither a robust prognostic marker in stage I nor stage IV CRC without immunotherapy.
Authors: Anna M Dahlin; Maria L Henriksson; Bethany Van Guelpen; Roger Stenling; Ake Oberg; Jörgen Rutegård; Richard Palmqvist Journal: Mod Pathol Date: 2011-01-14 Impact factor: 7.842
Authors: David Tougeron; Emilie Fauquembergue; Alexandre Rouquette; Florence Le Pessot; Richard Sesboüé; Michèle Laurent; Pascaline Berthet; Jacques Mauillon; Frédéric Di Fiore; Jean-Christophe Sabourin; Pierre Michel; Mario Tosi; Thierry Frébourg; Jean-Baptiste Latouche Journal: Mod Pathol Date: 2009-06-05 Impact factor: 7.842
Authors: A Buckowitz; H-P Knaebel; A Benner; H Bläker; J Gebert; P Kienle; M von Knebel Doeberitz; M Kloor Journal: Br J Cancer Date: 2005-05-09 Impact factor: 7.640
Authors: T Chiba; H Ohtani; T Mizoi; Y Naito; E Sato; H Nagura; A Ohuchi; K Ohuchi; K Shiiba; Y Kurokawa; S Satomi Journal: Br J Cancer Date: 2004-11-01 Impact factor: 7.640
Authors: Loraine Kay D Cabral; Cynthia A Mapua; Filipinas F Natividad; Caecilia H C Sukowati; Edgardo R Cortez; Ma Luisa D Enriquez Journal: World J Gastrointest Oncol Date: 2021-12-15